Approximately 40-50% of patients undergoing thoracic endovascular aortic repair require left subclavian artery coverage for adequate proximal landing zone. Many of these patients undergo left subclavian artery revascularisation. However, outcomes data for left subclavian artery revascularisation in the context of thoracic endovascular aortic repair remain limited. In this study, 70 left subclavian artery revascularisation procedures, performed on thoracic endovascular aortic repair patients at a tertiary hospital, were retrospectively reviewed. Particular emphasis was placed on revascularisationrelated outcomes during staging interval between revascularisation and thoracic endovascular aortic repair. Forty-six (66%) carotid-subclavian bypass, 17 (24%) carotid-carotid-subclavian bypass and 7 (10%) aorto-inominate-carotid-subclavian bypass procedures were performed. There were no strokes or mortalities following left subclavian artery revascularisation procedures alone. Three (10%) minor complications occurred including a seroma, a haematoma and a temporary neuropraxia. Separation of complications following left subclavian artery revascularisation from those of the associated thoracic endovascular aortic repair can be difficult. Early outcomes data from patients who underwent left subclavian artery revascularisation in isolation indicate that the procedure is safe with low complication rates.
Introduction
Thoracic endovascular aortic repair (TEVAR) is gradually overtaking open approaches in the management of pathologies affecting the descending thoracic aorta. 1, 2 This change in practice has been supported by evidence of reduced early complications and mortality rates after endovascular repair of thoracic aortic aneurysms, type B aortic dissections and traumatic aortic injuries. [3] [4] [5] Approximately 40-50% of patients undergoing TEVAR require coverage of the left subclavian artery (LSA) in order to achieve an adequate proximal landing zone during stent deployment. 6, 7 The LSA contributes significantly to perfusion of the left arm, spinal cord and the posterior circulation of brain. The risks associated with LSA coverage during TEVAR has been well characterised in the literature and they include increased risk of strokes, spinal cord ischaemia and left arm ischaemia. There is also evidence of a risk reduction following the LSA revascularisation in these patients. 6, 8, 9 Current guidelines from the Society of Vascular Surgery recommend routine revascularisation in cases where the LSA is covered during TEVAR, although this is admittedly based on weak evidence. 10 There are also proponents of selective LSA revascularisation in patients at higher risk of complications from LSA coverage. These include patients with dominant left vertebral arteries, incomplete circle of Willis, left arm arterio-venous fistula and those with existing left internal mammary artery -coronary circulation bypass. 11 The decision to revascularise the LSA is a balance of risks, and the risk of neurological complications following LSA coverage needs to be weighed up against risk of complications from the revascularisation procedure. Adequate understanding of outcomes following the LSA revascularisation is therefore crucial to such decision-making. Outcomes data following the LSA revascularisation procedures are very limited and the risk profile of LSA revascularisation, in the context thoracic aortic pathology, remains poorly understood. This study reports our experiences and early outcomes following the LSA revascularisation in patients undergoing TEVAR procedures at a tertiary referral institution.
Patients and methods

Study design
All consecutive LSA revascularisation cases were identified from operating theatre and procedure records and retrospectively reviewed. Data pertaining to patients' demographics, medical history, drugs history, operative procedure, imaging reports and 30-day perioperative outcomes were collated from clinical notes and the hospital's electronic records system. Outcomes data for all the LSA revascularisation procedures were reported. Patients who underwent revascularisation procedures separately from their TEVAR procedures represented the group of interest for the study. Outcomes data for staged LSA revascularisation procedures (prior to TEVAR) were reported up to 30 post-operative days but censored at the time of TEVAR in order to capture revascularisation-related outcomes only. Outcomes of interest were 30-day mortality, morbidities and reinterventions.
Pre-operative preparation and revascularisation decision
All patients undergoing TEVAR with anticipated LSA coverage were imaged pre-operatively via computed tomography angiography (CTA) AE colour duplex ultrasound scan in order to assess the anatomy and the pathology of the aorta and head/neck vasculature. Decision to revascularise the LSA and the choice of procedure was made by a multidisciplinary team of vascular surgeons and interventional radiologists based on assessment of individual patients' risk factors and potential benefits from the procedure. Patients undergoing elective TEVAR with LSA coverage, who were perceived to be at high risk of brain, spinal cord or left arm hypoperfusion, were scheduled for prophylactic LSA revascularisation (staged) or simultaneous LSA revascularisation during their TEVAR procedures. In emergency cases, LSA revascularisation was performed at the discretion of the operating surgeon.
Procedures and perioperative care
LSA revascularisation procedures performed include aorta-inominate-left common carotid-left subclavian artery bypass (AICSB), right carotid-left carotid-left subclavian artery bypass (CCSB) and left carotid-left subclavian artery bypass (CSB). The procedures were chosen based on the aortic arch vessels requiring coverage for achievement of an adequate landing zone. Proximal landing zones were defined based on the Ishimaru classification system. 12 Re-inforced PTFE grafts were used in all bypass procedures.
CSBs were performed in the standard fashion and as previously described via a supraclavicular incision. 13 CCSBs were performed through a further incision over the right sternocleidomastoid muscle. Heparinbonded PTFE was used for the bypass conduit and tunnelled retro-oesophageally where possible. Patients were usually on an anti-platelet agent during surgery as part of standard practice for patients with arterial pathology. All patients were assessed pre-operatively for the presence of a transcranial doppler (TCD) acoustic window. Intra-operative TCD monitoring for middle cerebral artery hypoperfusion and emboli was performed in all suitable patients and heparin was given during the procedure.
All patients, except those already on long-term anticoagulation or where contraindicated, were commenced on lifelong anti-platelet therapy post-operatively. They also underwent routine CT scanning following their TEVAR to check grafts patency. Patients with suspected neurological complications were assessed by a neurologist post-operatively and all necessary imaging performed.
Results
Patient demographics and procedures
Seventy patients underwent LSA revascularisation in association with thoracic aortic surgery, over a 12year period (2004-2015) at our institution. The majority of patients were male (67%), and the median age at LSA revascularisation was 69 (IQR 60-76). The main risk factors for aortic diseases were hypertension, smoking and dyslipidaemia. The majority of the procedures were performed electively (83%) and indications for TEVAR with LSA coverage were thoracic aortic aneurysms (38%), chronic type B dissections (26%), thoracoabdominal aneurysms (16%), acute type B dissections (10%) and type A dissection (6%). Twenty-nine (41%) of the LSA revascularisations were staged prior to TEVAR thus allowing observation of revascularisation-specific outcomes. The remaining 41 (59%) had simultaneous TEVAR and LSA revascularisation. Patient demographics and indication for TEVAR for both groups are described in Table 1 . All of the staged revascularisation procedures were performed electively. Median interval between LSA revascularisation and TEVAR for staged patients was 46.5 days (interquartile range: 28-68). Most patients required LSA coverage only (proximal landing zone 2; 55%), while the remaining required additional coverage of the left common carotid artery (proximal landing zone 1; 30%) and the innominate artery (proximal landing zone 3; 15%). In line with the number of arch vessels covered, the most common procedures performed were CSB (66%) followed by CCSB (24%) and AICSB (10%). Table 2 summarises the procedure details.
Outcomes
There were no strokes, spinal cord ischaemia or deaths following LSA revascularisation alone among the staged cases. All grafts remained patent after 30 postoperative days. There were three complications (10%).
One patient developed a hoarse voice (likely secondary to neuropraxia of the recurrent laryngeal nerve). This resolved prior to discharge. Another patient had neck haematoma that was managed conservatively. The last patient developed a seroma that was diagnosed on Duplex scanning. It is possible that this patient may have had a lymph leak secondary to a thoracic duct injury. However, we are unable to confirm this as an aspirate was not taken. Nevertheless, the patient made good recovery with antibiotics and conservative management. All patients experienced full recovery prior to their TEVAR procedures.
Conversely, there were four mortalities, one paraplegia, one stroke and three haematomas following 41 simultaneous LSA revascularisation and TEVAR. Two patients died of myocardial infarction, one developed pneumonia and died of sepsis and the last patient died following mesenteric ischaemia. Two of the haematoma cases affected the neck wounds and one patient required re-intervention in theatre for haemorrhage control. The third haematoma occurred in the groin and also required re-intervention in the operating theatre. The post-operative complications are summarised in Table 3 . While the study focused on early outcomes, two patients were noted to develop graft infection at 3 and 18 months post-operatively thus requiring graft removal.
Discussion
The LSA revascularisation in TEVAR patients represents a balance of complications risks from the additional procedure, against risks of neurological complications associated with LSA coverage. However, the risks and outcomes associated with LSA revascularisation in the context of TEVAR are poorly understood. A vast majority of available evidence in this area come from retrospective studies of revascularisation in the context of occlusive LSA disease. Outcomes from these studies may not be relevant to TEVAR patients due to differences in procedures and potential differences in perioperative risks. This study set out to report 30-days perioperative outcomes following the LSA revascularisation in association with TEVAR at a single tertiary institution. Among 70 reviewed LSA revascularisation procedures, 29 were performed separately from the TEVAR thus allowing observation of outcomes associated with the revascularisation procedure rather than those secondary to TEVAR. Evidence from these 29 patients indicates a low early complications rate of 10%. The observed complications were also relatively minor or transient. Notably, there were no strokes or mortality following the LSA revascularisation procedures.
Separation of LSA revascularisation-related complications from those resulting from the associated TEVAR procedure can be fraught with difficulty. This is particularly pertinent to the patients who undergo simultaneous revascularisation and TEVAR procedures. The nature of the observed complications (strokes and mortalities) among these patients suggest that they are likely due to the TEVAR procedures rather than the LSA revascularisation, with the exception of the two neck haematomas reported within this group. There are limited studies to which our findings can be compared due to differences in procedures performed, study methodologies and durations of follow-up. A recent study, by Saouti et al., 14 of LSA revascularisation outcomes among 51 patients who underwent TEVAR with LSA coverage reported an overall complication rates of 22.6%. Majority of the complications reported were nerve injuries (15%). They reported no strokes or deaths. Complications from TEVAR could not be separated from those of LSA revascularisation in this study. Also, varied follow-up periods and procedures make comparisons difficult.
Other available studies have focused on comparison of outcomes after TEVAR procedures with and without LSA revascularisation, with little emphasis on outcomes specifically associated with the LSA revascularisation procedure. 11, 15, 16 Nerve injuries, especially phrenic nerve injuries, have also been commonly reported in these studies. Furthermore, a meta-analysis of complications associated with LSA revascularisation among TEVAR patients reported a phrenic nerve injury rate of 4.40% (CI: 1.60%-12.20%). 9 No phrenic nerve damage was recorded among the patients reviewed in our study. Numerous studies have investigated outcomes following CSB or carotid-subclavian transposition (CST) procedures in the context of occlusive LSA disease with reported complication rates ranging from 8 to 23% and stroke rates up to 10.8%. 13, [17] [18] [19] [20] Complications, especially those secondary to occlusive or embolic phenomena, cannot be directly extrapolated from patients with occlusive LSA disease to TEVAR patients. The underlying LSA disease and the intra-operative endarterectomy among the former patients can potentially predispose them to higher complication rates. 18 Also, CST accounts for majority of the procedures performed in these studies.
This study is limited by the retrospective approach to data collection and small sample size. However, focus on the window between LSA revascularisation and TEVAR procedures allowed for specific identification of complications associated with the LSA revascularisation procedure alone. The aim of the study was to identify early post-operative outcomes; late complications of the procedure were therefore not captured. However, the risk of longer term complications does exist. For example, two of the CSB grafts required removal at 3 and 18 months after the initial operation due to infection. The aetiology of infection remained unclear in both of these cases especially since blood cultures were inconclusive. Possible sources include direct contamination or haematogenous spread from a transient bacteraemia or surgery. It is, however, notable that there was no evidence of TEVAR graft infection in either cases. This highlights that a risk of future graft infection exists and the LSA revascularisation graft should be monitored together with the routine surveillance of the TEVAR endograft.
In conclusion, our experience indicates that LSA revascularisation in patients undergoing TEVAR is associated with low complication rates. Current research priorities include further definition of the risk profile and risk reduction associated with LSA revascularisation in order to guide patient selection and help to establish ideal revascularisation protocols.
